Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030567 (Parkinson's disease)
 63,064 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Paralysis agitans may be mimicked by other disease processes and drugs which disturb the structural or functional integrity of the dopaminergic nigrostriatal system. In another group of patients, isolated symptoms or signs such as tremor or increased muscle tone are considered out of the context of the total clinical picture and may suggest parkinsonism.
 ...
PMID:Differential diagnosis of paralysis agitans. 26 20

Involvement of the urinary bladder in Parkinson's disease was recognized in the 1950's, when the accidental discovery of a neurosurgical means of treating the disease brought more attention to it, with increasing research and study. In more recent years, the advent of more specific medical treatment has led to closer examination of the disease, and has enlarged our awareness of its complications. This has been paralleled by progress in the field of urology, with more precise methods of measuring dysfunction of the urinary bladder.
 ...
PMID:Neurogenic dysfunction of the urinary bladder in Parkinson's disease. 26 23

This article is written in order to help the patient with Parkinson's disease function as independently as possible. It is not meant to be a complete treatment program, but a collection of helpful ideas based on the experience of physiotherapists who work with these patients daily, and on information acquired from such patients. The techniques are applicable at home and in the hospital.
 ...
PMID:Home care of patients with Parkinson's disease. 26 25

Methods and aids for helping the individual with Parkinson's disease overcome some of the problems encountered in daily living. Only by a continuous, on-going program, much patience, and knowledge of how and what can be done can the patient be helped to maintain his interests and independence within the range of his abilities.
 ...
PMID:Self-care aids for the parkinsonian patient and his family. 26 26

Levodopa is at present the most effective treatment of Parkinson's disease. Its use in combination with a peripheral decarboxylase inhibitor prolongs the elevation of plasma levels and decreases the incidence of peripheral side effects. Severe psychiatric and neurologic side-effects may necessitate reduction or cessation of the drug.
 ...
PMID:Levodopa in the treatment of Parkinson's disease. 26 29

Psychiatric problems constitute one of the prime reasons for failure in levodopa therapy in Parkinson's disease. While a variety of symptoms may be seen, the levodopa itself does not produce a defined set of psychiatric symptoms. The single most important factor determining the psychiatric response to levodopa therapy is the mental state of the patient before therapy.
 ...
PMID:Psychiatric disturbances occurring during levodopa therapy of Parkinson's disease. 26 30

In contrast to antipsychosis drugs which inhibit the dopamine-activated adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] of caudate nucleus, dopaminergic drugs for treatment of Parkinson's disease stimulate this cyclase. Stimulants and inhibitors of cholinergic neurons inhibited this adenylate cyclase activity competitively and specifically. Thus, the mechanism by which dopaminergic medications ameliorate the effects of Parkinson's disease includes activation of the dopamine-sensitive adenylate cyclase. Excessive activation might be present during the psychotic episodes seen in patients with parkinsonism who are overtreated. The enzymatic effects of the drugs that affect cholinergic mechanisms seem to be generally in keeping with the pharmacological reciprocity between psychoses and extrapyramidal function, except for the anticholinergic ones which inhibited this cyclase although they can be hallucinogenic.
 ...
PMID:Opposing effects of dopaminergic to cholinergic compounds on a cerebral dopamine-activated adenylate cyclase. 26 41

Five patients with Parkinson's disease, when first seen, manifested an abnormal increase in appetite. This bulimia decreased concomitantly with clinical improvement in the parkinsonism during treatment with L-dopa plus a decarboxylase inhibitor. A possible role of dopamine in the central control of appetite is discussed. Abnormally increased appetite (bulimia) is proposed as a new autonomic sign in Parkinson's disease.
 ...
PMID:Increased appetite (bulimia) in Parkinson's disease. 26 36

In principle tremors can be produced by (1) mechanical oscillators (combination of masses and springs), (2) reflex oscillators arising from sensory feedback pathways, or (3) central oscillators generated by single "pacemaker" neurones or interconnected networks. Recent studies supporting each of these mechanisms under certain conditions are discussed. Differences between these mechanisms are clarified by recent studies in Edmonton on the premammillary cat. This preparation shows a prominent reflexly-induced tremor which can be modified by mechanical loading and electrical stimulation. It also shows spontaneous stepping on a treadmill which is known to be produced by a spinal "stepping generator", but can be modified in interesting ways by sensory perturbations. The applicability of these animal studies to human tremors is considered in relation to preliminary studies in Calgary on patients with Parkinson's disease or essential tremor. We have attempted to modify these tremors by application of torque pulses applied to the wrist. The results are described in terms of a normalized "resetting" index which has a high value (greater than 0.6) for all essential tremor patients studied, and a wide range of values for different parkinsonian patients. The resetting index may be useful in determining the relative importance of peripheral and central factors in producing tremor in a variety of patients.
 ...
PMID:Modifications of ongoing tremors and locomotion by sensory feedback. 28 51

L-DOPA-psychosis is a frequent side effect of the combined treatment of Parkinson's disease with L-DOPA and peripherally active decarboxylase inhibitors. Regional human post-mortem brain studies showed a significant increase of noradrenaline and serotonin particularly in extrastriatal areas, whereas the lenticular nuclei were not involved. The significance of extrastriatal neurotransmitter dysfunctions for psychiatric disorders is discussed.
 ...
PMID:Toxic delirium after L-dopa medication. 29 Jul 36


<< Previous 1 2 3 4 5 6 7 8 9 10